AGIANA PHARMACEUTICALS AS: årsregnskap 2025 vs 2024
Grew 65% on revenue, weaker earnings, cash halved-plus
approved 2026-05-19; registry 2026-07-01; journal 2026 614597
Summary
What changed
Comparing Årsregnskap 2025 with 2024 for AGIANA PHARMACEUTICALS AS. Revenue 534.6k NOK → 881.5k NOK (+64.9%). Net result -4.50m NOK → -15.17m NOK. Equity 13.42m NOK → 3.25m NOK.
On the constructive side: revenue rose; owners injected capital. Pressures included: operating result weakened; net result weakened; equity eroded.
Also worth watching: sharp cash drawdown. All figures are taken from the published annual accounts for AGIANA PHARMACEUTICALS AS.
At a glance
Scorecard
What improved
-
↑
Revenue rose
Operating income / revenue moved from 534.6k NOK to 881.5k NOK (+64.9% YoY). Calculated
-
↑
Owners injected capital
Paid-in equity rose 23.82m NOK → 28.83m NOK (+5.00m NOK). Reported fact
What deteriorated
-
↓
Operating result weakened
Operating result -4.66m NOK → -15.45m NOK (op. margin -871.7% → -1753.1%). Calculated
-
↓
Net result weakened
Net result -4.50m NOK → -15.17m NOK (net margin -842.0% → -1720.7%). Calculated
-
↓
Equity eroded
Book equity 13.42m NOK → 3.25m NOK (equity ratio 94.9% → 40.5%). Calculated
-
↓
Cash fell
Bank deposits 13.62m NOK → 4.68m NOK (-65.7% YoY). Calculated
Things to notice
-
·
Sharp cash drawdown
Cash fell by more than 60% YoY (13.62m NOK → 4.68m NOK). Check whether funds moved to group receivables, investments, or operating burn. Interpretation